**Supplementary file**

**Methods**

The following “Summary of Product Characteristics” and publications were used for the identification of phase III clinical trials for the respective drug: ocrelizumab\(^1\); cladribine\(^2\); daclizumab\(^3\); dimethyl fumarate\(^4\); teriflunomide\(^5\); alemtuzumab\(^6\); fingolimod\(^7\); natalizumab\(^8\); mitoxantrone\(^9,10\); glatiramer acetate\(^11\); peginterferon β-1a\(^12\); interferon β-1a\(^13,14\); interferon β-1b\(^15\).

**References**

1. European Medicines Agency - Committee for Medicinal Products for Human. Ocrevus EPAR - Product Information: Ocrevus - EMEA/H/C/004043, https://www.ema.europa.eu/en/documents/assessment-report/ocrevus-epar-public-assessment-report_en.pdf (2020, accessed 19 May 2020).

2. European Medicines Agency - Committee for Medicinal Products for Human. Mavenclad EPAR - Product Information: Mavenclad - EMEA/H/C/004230-IB/0012, https://www.ema.europa.eu/en/documents/product-information/mavenclad-epar-product-information_en.pdf (2020, accessed 12:05:2020, 19:46).

3. European Medicines Agency - Committee for Medicinal Products for Human. Zinbryta EPAR - Product Information: EMEA/H/C/003862 - IB/0015, https://www.ema.europa.eu/en/documents/product-information/zinbryta-epar-product-information_en.pdf (2016, accessed 14 October 2019).

4. European Medicines Agency - Committee for Medicinal Products for Human. Tecfidera EPAR - Product Information: EMEA/H/C/002601 - II/0058,
5. European Medicines Agency - Committee for Medicinal Products for Human. Aubagio EPAR - Product Information: Aubagio - EMEA/H/C/002514, https://www.ema.europa.eu/en/documents/product-information/aubagio-epar-product-information_en.pdf (2020, accessed 19 May 2020).

6. European Medicines Agency - Committee for Medicinal Products for Human. Lemtrada EPAR - Product Information: EMEA/H/C/003718 - A20/0028, https://www.ema.europa.eu/en/documents/product-information/lemtrada-epar-product-information_en.pdf (2020, accessed 19 May 2020).

7. European Medicines Agency - Committee for Medicinal Products for Human. Gilenya EPAR - Product Information: EMEA/H/C/002202 - PSUSA/00001393/201902, https://www.ema.europa.eu/en/documents/product-information/gilenya-epar-product-information_en.pdf (2019, accessed 9 October 2019).

8. European Medicines Agency - Committee for Medicinal Products for Human. Tysabri EPAR - Product Information: EMEA/H/C/000603 - PSUSA/00002127/201908, https://www.ema.europa.eu/en/documents/product-information/tysabri-epar-product-information_en.pdf (2020, accessed 19 May 2020).

9. European Medicines Agency - Committee for Medicinal Products for Human. Novantrone and associated names Article-30 referral - Assessment report, https://www.ema.europa.eu/en/documents/referral/novantrone-associated-names-article-30-referral-assessment-report_en.pdf (2016, accessed 10 October 2019).
10. Kieseier BC, Gold R and Hartung H-P. Mitoxantron zur Therapie der Multiplen Sklerose. *Nervenarzt* 2003; 74: 906–910.

11. Weinstock-Guttman B, Nair KV, Glajch JL, et al. Two decades of glatiramer acetate: From initial discovery to the current development of generics. *J Neurol Sci* 2017; 376: 255–259.

12. European Medicines Agency - Committee for Medicinal Products for Human. Plegridy EPAR - Product Information: EMEA/H/C/002827 - II/0052/G, https://www.ema.europa.eu/en/documents/product-information/plegridy-epar-product-information_en.pdf (2019, accessed 20 May 2020).

13. European Medicines Agency - Committee for Medicinal Products for Human. Rebif EPAR - Product Information: EMEA/H/C/000136 - II/0144, https://www.ema.europa.eu/en/documents/product-information/rebif-epar-product-information_en.pdf (2020, accessed 20 May 2020).

14. European Medicines Agency - Committee for Medicinal Products for Human. Avonex EPAR - Product Information: EMEA/H/C/000102 - II/0182/G, https://www.ema.europa.eu/en/documents/product-information/avonex-epar-product-information_en.pdf (2019, accessed 20 May 2020).

15. European Medicines Agency - Committee for Medicinal Products for Human. Betaferon EPAR - Product Information: EMEA/H/C/000081 - II/0124/G, https://www.ema.europa.eu/en/documents/product-information/betaferon-epar-product-information_en.pdf (2019, accessed 20 May 2020).